Stocktoria
AXIM BIOTECHNOLOGIES, INC. AXIM
AXIM BIOTECHNOLOGIES, INC. (AXIM) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2023 revenue was $39,518 at a -20395.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AXIM | AXIM BIOTECHNOLOGIES, INC. | 3/9 | — | — | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | 1/9 | — | — | — |
| ALT | Altimmune, Inc. | 4/9 | 0.63 | — | — |
| LYEL | Lyell Immunopharma, Inc. | 1/9 | -13.93 | — | — |
| IBO | IMPACT BIOMEDICAL INC. | 3/9 | -2.38 | — | — |
| TLPH | TALPHERA, INC. | 4/9 | — | — | — |
| HCWB | HCW Biologics Inc. | 2/9 | — | — | — |
About AXIM BIOTECHNOLOGIES, INC.
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. In addition, the company develops a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring, as well as COVID-19 rapid diagnostic tools. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
FAQ
Is AXIM financially healthy?
AXIM BIOTECHNOLOGIES, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does AXIM pay a dividend?
No, AXIM BIOTECHNOLOGIES, INC. does not currently pay a dividend.
How profitable is AXIM?
In FY2023, AXIM BIOTECHNOLOGIES, INC. had a net margin of -20395.0%.
Is AXIM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on AXIM BIOTECHNOLOGIES, INC.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2023-12-31. Facts plus Stocktoria's own computed scores — not investment advice.